Hospitality Properties Trust (Nasdaq: HPT) today announced a regular quarterly common share distribution of $0.51 per common share ($2.04 per share per year). This distribution will be paid...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hyperion Therapeutics, Inc. Juan E. Monteverde, a...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) (“Hyperion” or “the Company”) in connection...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion” or "the Company...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) (“Hyperion” or “the Company”) in connection...
Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire MERION, Pa., April 7, 2015 MERION, Pa., April 7, 2015 /PRNewswire/ -- The Law Offices of Marc S. Henzel...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion Therapeutics, Inc. Over the Proposed Sale of the Company to Horizon Pharma, Plc...
WeissLaw LLP: The Hyperion Therapeutics, Inc. Acquisition by Horizon Pharma Plc Is the Subject of a Legal Investigation PR Newswire NEW YORK, April 3, 2015 NEW YORK, April 3, 2015 /PRNewswire/...
HPTX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Hyperion Therapeutics, Inc. Concerning the Sale of the Company to Horizon Pharma...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales